It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF, is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain.
Of course, it's not hard to find stocks that have performed both better and worse than the sector av